Navigation Links
Intellect Neurosciences Obtains Two New Patents in Japan for Its Alzheimer's Immunotherapy Programs
Date:11/8/2011

al trials.

IN-N01 is a proprietary product of the company's ANTISENILIN technology platform, which includes other products in development such as Bapineuzumab, which are being developed independently by major pharmaceutical companies.  IN-N01 has similar specificity for the beta amyloid toxin as does Bapineuzumab. However, in contrast to Bapineuzumab, IN-N01 may have reduced risk of inflammation from immune responses in patients.  In addition, IN-N01 is being developed as an antibody drug conjugate with OX2 under Intellect's new CONJUMAB-A platform technology.  This combination is expected to increase clearance of beta amyloid from the brain as well as reduce inflammation, which can result in vasogenic edema, a side-effect of immunotherapy in some patients that result from antibody-mediated dissolution of plaque.  The CONJUMAB-A platform for which IN-N01-OX2 is the flagship molecule, is applicable to a broad range of diseases including: Alzheimer's, Parkinson's, Huntington's, Age-Related Macular Degeneration, Glaucoma, Cerebral Angiopathy, Frontotemporal Dementia, Progressive Supranuclear Palsy, Pick's disease, Cortical Basal Degeneration and Peripheral Amyloidosis.  

About Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. develops innovative approaches aimed at arresting or preventing Alzheimer's disease, and other neurodegenerative diseases especially focused on proteinopathies. Intellect's pipeline includes small neuroprotective molecules and neoepitope-based immunotherapy approaches including monoclonal antibodies and vaccines targeting beta amyloid and abnormal tau proteins. The company is currently developing three separate platform technologies:  ANTISENILIN® is Intellect's Alzheimer's beta amyloid monoclonal antibody platform technology which underlies several products in advanced clinical development and is licensed to major pharmaceutical companies.  The company's RECALL-VAX
'/>"/>

SOURCE Intellect Neurosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
3. Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimers Therapeutic Antibody
4. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
5. Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
6. New Study Confirms That the Supports Intensity Scale Assessment is Effective in Measuring the Support Needs of People With Intellectual Disability and Making Funding Decisions
7. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
8. NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds
9. VisEn Acquires Key Fluorescence Agent Intellectual Property Portfolio and Technology Platforms From Bayer Schering Pharma
10. First iPierian Patent for Induced Pluripotent Stem Cell Technology Granted by United Kingdom Intellectual Property Office
11. Limited Healthcare Infrastructure and Weak Intellectual Property Protection are Among the Challenges Pharma Faces with Emerging Market Expansion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... GENEVA, Ill. , Jan. 15, 2014 The ... a Medical Fitness Center by the Medical Fitness Association, ... centers to achieve their full potential. The Cadence Fitness ... in the western suburbs and second in the Chicagoland ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... – Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Analysis Insulin Pumps ...
(Date:1/15/2014)... Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... tender offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary ... common stock of Solta Medical, Inc. (NASDAQ: ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Mass., May 12, 2011 PLC Systems Inc. (OTCBB: ... today announced it will demonstrate its innovative new product, ... Association of Percutaneous Cardiovascular Interventions (EAPCI).  More than 11,000 ... expected to attend this event, which will take place ...
... CVS Caremark was selected as one of 20 finalists ... Health Care Consumer Empowerment and Protection. URAC, the nation,s ... 12th Annual Quality Summit, October 4-6, 2011 in Chicago, ... Pharmacy Advisor program was selected by a distinguished panel ...
Cached Medicine Technology:PLC to Demonstrate RenalGuardĀ® at EuroPCR 2011 2PLC to Demonstrate RenalGuardĀ® at EuroPCR 2011 3CVS Caremark Named as Finalist for 2011 URAC Award for Best Practices in Health Care Consumer Empowerment and Protection 2CVS Caremark Named as Finalist for 2011 URAC Award for Best Practices in Health Care Consumer Empowerment and Protection 3
(Date:4/24/2014)... A Finnish team of researchers was the first in ... which is a tumour of the jaw. , Ameloblastoma ... recur after treatment. Ameloblastoma is most often found in ... by surgery, often resulting in tissue deficiencies in the ... suitable drug therapy could reduce the need for surgery ...
(Date:4/24/2014)... the University of York reveals that a process that ... nervous system may also play a pivotal role in ... led by Dr Will Brackenbury, a Medical Research Council ... studied how voltage-gated sodium channels assist in the metastasis ... membranes of excitable cells, such as neurons, where they ...
(Date:4/23/2014)... SPOKANE, Wash.Researchers at Washington State University Spokane have ... are about to nod off behind the wheel. ... steering wheel movementswhich are more variable in drowsy ... to currently available video-based driver drowsiness detection systems. ... detect when a car is drifting out of ...
(Date:4/23/2014)... Ind. - Purdue University researchers have developed a way ... cell by using tiny gold particles with tails of ... of agricultural and biological engineering, used gold nanoparticles to ... as BRCA1 messenger RNA splice variants, which can indicate ... of these mRNA splice variants in a cell can ...
(Date:4/23/2014)... program could help doctors predict which patients might suffer ... , The program, which assesses brain scans using pattern ... and passport control, has been developed by researchers at ... by the Wellcome Trust, which used the software are ... , Stroke affects over 15 million people each year ...
Breaking Medicine News(10 mins):Health News:Breast cancer replicates brain development process 2Health News:WSU innovation improves drowsy driver detection 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3
... Highlights Key Issues and Offers Suggestions on ... Improvements for Hospital Administrators, NEW YORK, March ... delivery of a baby is a significant decision. But,there are ... departments,around the country that must function properly in order to ...
... on more than 17,000 people with coronary artery disease ... Treatment with an ACE inhibitor drug was as effective ... high-risk group of patients as a newer and more ... has found. , The study of more than 17,000 ...
... ANN ARBOR, Mich. An international blood pressure study ... significant that the study has been stopped early ... way high blood pressure is treated worldwide. , ... people who had high blood pressure and other cardiovascular ...
... 2008 New data from a clinical trial ... patients living with type 2 diabetes, ACTOS® (pioglitazone ... arteries compared to glimepiride, and prevented progression compared ... PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic ...
... new,public health campaign created by an alliance of ... in Washington, DC. The program,called EX(R), will change ... quitting, and guide them to valuable free resources ... Fairness Doctrine was applied to,tobacco in 1968-1970 have ...
... Industry Leaders,Association (RILA) today filed a friend-of-the-court (amicus) ... Court of Appeals for,the Ninth Circuit challenging the ... The case, Golden Gate Restaurant Association v. City ... Health Care Security Ordinance,which mandates health insurance coverage ...
Cached Medicine News:Health News:OB Challenges Create Hospital Opportunities in 2008 2Health News:OB Challenges Create Hospital Opportunities in 2008 3Health News:OB Challenges Create Hospital Opportunities in 2008 4Health News:ACE Inhibitor as Effective as More Expensive Blood Pressure Drug 2Health News:2-drug blood pressure therapy lowers cardiovascular risk 2Health News:2-drug blood pressure therapy lowers cardiovascular risk 3Health News:New data showed Actos prevented progression of atherosclerotic plaque volume in patients 2Health News:New National Public Health Program Shows Smokers How to Become an EX 2Health News:New National Public Health Program Shows Smokers How to Become an EX 3Health News:New National Public Health Program Shows Smokers How to Become an EX 4Health News:New National Public Health Program Shows Smokers How to Become an EX 5Health News:Retail Industry Leaders Association Files Amicus in California Health Care Litigation 2
... Triage BNP Test is the first ... measuring B-type natriuretic peptide (BNP) ,Cardiac ... in response to ventricular volume expansion ... of ventricular systolic and diastolic dysfunction. ...
... Building on over 20 years of ... platforms for the Life Sciences, the ... flexibility and possibilities for expansion according ... new easy-to-use software, Freedom EVOware, each ...
... (OSS) from Biomet Inc. offers the ... specifically for orthopaedic surgeons and oncologists ... their patients: significant bone loss, ligamentous ... arthroplasties, and multiple hip revision arthroplasties. ...
The generously sized STERILE VIEW Monk Hood from DePuy provides splash protection in the chin and neck areas from body fluids and liquids. Shoulder cut outs and ties ensure a comfortable fit. This pr...
Medicine Products: